GRDN Quote, Financials, Valuation and Earnings

Ensign Group has a net margin of -38.8% compared to Guardian Pharmacy Services's net margin of 7.25%. Guardian Pharmacy Services's return on equity of -109.2% beat Ensign Group's return on equity of 15.07%.

Guardian Pharmacy Services has a consensus price target of --, signalling upside risk potential of 22.14%. On the other hand Ensign Group has an analysts' consensus of $169.50 which suggests that it could grow by 29.55%. Given that Ensign Group has higher upside potential than Guardian Pharmacy Services, analysts believe Ensign Group is more attractive than Guardian Pharmacy Services.

Guardian Pharmacy Services has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ensign Group has a beta of 0.935, suggesting its less volatile than the S&P 500 by 6.508%.

Guardian Pharmacy Services has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ensign Group offers a yield of 0.19% to investors and pays a quarterly dividend of $0.06 per share. Guardian Pharmacy Services pays 160.75% of its earnings as a dividend. Ensign Group pays out 6.16% of its earnings as a dividend. Ensign Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Guardian Pharmacy Services's is not.

Guardian Pharmacy Services quarterly revenues are $314.4M, which are smaller than Ensign Group quarterly revenues of $1.1B. Guardian Pharmacy Services's net income of -$122M is lower than Ensign Group's net income of $78.4M. Notably, Guardian Pharmacy Services's price-to-earnings ratio is -- while Ensign Group's PE ratio is 31.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardian Pharmacy Services is 1.03x versus 1.85x for Ensign Group. Usually stocks with elevated PS ratios are considered overvalued.

LifeStance Health Group has a net margin of -38.8% compared to Guardian Pharmacy Services's net margin of -1.91%. Guardian Pharmacy Services's return on equity of -109.2% beat LifeStance Health Group's return on equity of -6.64%.

Guardian Pharmacy Services has a consensus price target of --, signalling upside risk potential of 22.14%. On the other hand LifeStance Health Group has an analysts' consensus of $8.70 which suggests that it could grow by 15.69%. Given that Guardian Pharmacy Services has higher upside potential than LifeStance Health Group, analysts believe Guardian Pharmacy Services is more attractive than LifeStance Health Group.

Guardian Pharmacy Services has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LifeStance Health Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Guardian Pharmacy Services has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeStance Health Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardian Pharmacy Services pays 160.75% of its earnings as a dividend. LifeStance Health Group pays out -- of its earnings as a dividend.

Guardian Pharmacy Services quarterly revenues are $314.4M, which are larger than LifeStance Health Group quarterly revenues of $312.7M. Guardian Pharmacy Services's net income of -$122M is lower than LifeStance Health Group's net income of -$6M. Notably, Guardian Pharmacy Services's price-to-earnings ratio is -- while LifeStance Health Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardian Pharmacy Services is 1.03x versus 2.35x for LifeStance Health Group. Usually stocks with elevated PS ratios are considered overvalued.

PACS Group has a net margin of -38.8% compared to Guardian Pharmacy Services's net margin of -1.11%. Guardian Pharmacy Services's return on equity of -109.2% beat PACS Group's return on equity of --.

Guardian Pharmacy Services has a consensus price target of --, signalling upside risk potential of 22.14%. On the other hand PACS Group has an analysts' consensus of $31.83 which suggests that it could grow by 140.07%. Given that PACS Group has higher upside potential than Guardian Pharmacy Services, analysts believe PACS Group is more attractive than Guardian Pharmacy Services.

Guardian Pharmacy Services has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PACS Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Guardian Pharmacy Services has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PACS Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardian Pharmacy Services pays 160.75% of its earnings as a dividend. PACS Group pays out 71.23% of its earnings as a dividend. PACS Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Guardian Pharmacy Services's is not.

Guardian Pharmacy Services quarterly revenues are $314.4M, which are smaller than PACS Group quarterly revenues of $981.8M. Guardian Pharmacy Services's net income of -$122M is lower than PACS Group's net income of -$10.9M. Notably, Guardian Pharmacy Services's price-to-earnings ratio is -- while PACS Group's PE ratio is 20.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardian Pharmacy Services is 1.03x versus 0.59x for PACS Group. Usually stocks with elevated PS ratios are considered overvalued.

Pennant Group has a net margin of -38.8% compared to Guardian Pharmacy Services's net margin of 3.43%. Guardian Pharmacy Services's return on equity of -109.2% beat Pennant Group's return on equity of 13.06%.

Guardian Pharmacy Services has a consensus price target of --, signalling upside risk potential of 22.14%. On the other hand Pennant Group has an analysts' consensus of $36.00 which suggests that it could grow by 36.67%. Given that Pennant Group has higher upside potential than Guardian Pharmacy Services, analysts believe Pennant Group is more attractive than Guardian Pharmacy Services.

Guardian Pharmacy Services has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pennant Group has a beta of 1.935, suggesting its more volatile than the S&P 500 by 93.465%.

Guardian Pharmacy Services has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pennant Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardian Pharmacy Services pays 160.75% of its earnings as a dividend. Pennant Group pays out -- of its earnings as a dividend.

Guardian Pharmacy Services quarterly revenues are $314.4M, which are larger than Pennant Group quarterly revenues of $180.7M. Guardian Pharmacy Services's net income of -$122M is lower than Pennant Group's net income of $6.2M. Notably, Guardian Pharmacy Services's price-to-earnings ratio is -- while Pennant Group's PE ratio is 38.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardian Pharmacy Services is 1.03x versus 1.24x for Pennant Group. Usually stocks with elevated PS ratios are considered overvalued.